Editorial
Esketamine for treatment resistant depression
BMJ · 23.09.2019 · l5572
DOI: 10.1136/bmj.l5572 ↗Kurz gefasst
Editorial in der Zeitschrift BMJ, online erschienen am 23.09.2019. Verfasst von Sameer Jauhar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK Sameer.jauhar@kcl.ac.uk. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Administration, IntranasalAdministration, OralAntidepressive AgentsDepressionDrug ApprovalDrug Therapy, CombinationHumansKetamineUnited StatesUnited States Food and Drug Administration
Substanzen
Antidepressive AgentsEsketamineKetamine
Autor:innen und Institutionen
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK Sameer.jauhar@kcl.ac.uk.
- Argyll and Bute Health and Social Care Partnership, Lochgilphead, NHS Highland, UK.
Zitieren
APA
Jauhar, S., & Morrison, P. (2019). Esketamine for treatment resistant depression. BMJ, l5572. https://doi.org/10.1136/bmj.l5572
Vancouver
Jauhar S, Morrison P. Esketamine for treatment resistant depression. BMJ. 2019:l5572. doi:10.1136/bmj.l5572
BibTeX
@article{Jauhar2019,
author = {Jauhar, Sameer and Morrison, Paul},
title = {Esketamine for treatment resistant depression},
journal = {BMJ},
year = {2019},
pages = {l5572},
doi = {10.1136/bmj.l5572}
}
EUVIMED